The LightSwitch Luciferase Assay System provides everything you need for reporter assays: pre-cloned human promoters and 3'UTRs in luciferase reporter vectors plus optimized luciferase reagents to measure promoter induction and miRNA target validation. Visit SwitchGear Genomics and explore our genome-wide collections and validated pathway sets.
Scientific Reports publishes 457 open access papers in its first year
Publishing technically sound research articles, Scientific Reports is Nature Publishing Group’s fastest growing journal. Given the speed and visibility offered, no wonder 93% of our authors said that they are “likely” or “very likely” to submit again.
First therapy targeting Parkinson's proteins enters clinical trials doi:10.1038/nm0712-992b An Austrian company has launched the world's first clinical trial involving a therapy directed against a protein that's a pathologic hallmark of Parkinson's disease. Full Text
FDA approves pertuzumab doi:10.1038/nbt0712-570 On June 8, the US Food and Drug Administration approved Genentech's monoclonal antibody Perjeta (pertuzumab) for metastatic HER2/neu-overexpressing breast cancer. Full Text
Canada approves stem cell product doi:10.1038/nbt0712-571b Canada and New Zealand have approved a stem cell therapy, Prochymal, produced by Osiris Therapeutics. It will be used to treat graft-versus-host disease. Full Text
Neighbouring cells help cancers dodge drugs doi:10.1038/nature.2012.10952 Cancers can resist destruction by drugs with the help of proteins recruited from surrounding tissues, find two studies published by Nature. Full Text
Liquid biopsy doi:10.1038/scibx.2012.668 A Cancer Research UK team has developed a platform to noninvasively monitor treatment response in cancer patients. The researchers will now test it in the early diagnosis of ovarian cancer. Full Text
FDA advisory committee meeting outcomes doi:10.1038/nrd3747 This analysis of the outcomes of advisory committee meetings held by the US FDA over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions. Full Text
Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text
Cancer: Of targets and anti-targets doi:10.1038/nrd3781 Polypharmacology is difficult to predict. Now, researchers have taken a systems pharmacology approach, identifying targets and anti-targets for the rational design of drugs with an optimized polypharmacological profile. Full Text
Metabolic disorders: Heart microRNA provides new route to metabolic control doi:10.1038/nrd3779 Researchers have discovered a novel role of the heart in systemic metabolic control and suggest that miR-208a inhibition may have applications in the treatment of metabolic disorders. Full Text
Anticancer drugs: Antipsychotic to anticancer agent? doi:10.1038/nrd3783 A new study has screened for compounds that selectively differentiate cancer stem cell-like cells and has identified dopamine receptor antagonists as promising candidates. Full Text
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars doi:10.1038/nrd3746 This review looks at the analytical technologies available to assess biosimilars, focusing on the assessment of post-translational modifications, three-dimensional structures and protein aggregation. Full Text
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma doi:10.1038/nrd3745 This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities. Full Text
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4–CD8–entheseal resident T cells doi:10.1038/nm.2817 The identification of an IL-23–responsive CD4–CD8– T cell population points to new therapeutic targets for this group of rheumatic disorders. Full Text
A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis doi:10.1038/nm.2826 Researchers have discovered a new axis that mediates the pathogenic progression of endometriosis, and suggest that the antibody to TNF-α etanercept might offer a therapy. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment